Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
US11472799B2 · kind B2 · utility
2Cited by
5References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 6, 2019 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | May 10, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/912
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.